Comorbid mood disorders and medical illness: A Food and Drug Administration perspective

Biological Psychiatry

Volumn 54, Issue 3, 2003, Pages 195-199

  Laughren, Thomas P ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; UNITED STATES;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; HUMANS; MOOD DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0141832633     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00529-8     Document Type: Editorial

References (6)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed:1994;American Psychiatric Press, Washington, DC.
2. Friedman J.H., Fernandez H.H. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry. 15:(3):2002;156-170.
3. Gareri P., De Fazio P., De Sarro G. Neuropharmacology of depression in aging and age-related diseases. Ageing Res Rev. 1:(1):2002;113-134.
4. Glassman A.H., Roose S.P., Bigger J.T. Jr. The safety of tricyclic antidepressants in cardiac patients Risk-benefit reconsidered . JAMA. 269:1993;2673-2675.
5. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am J Geriatr Psychiatry. 9:(4):2001;340-345.
6. Lyketsos C.G., Olin J. Depression in Alzheimer's disease Overview and treatment . Biol Psychiatry. 52:2002;243-252.